Gonadal dysfunction in male patients with neuroendocrine tumors

2021 ◽  
Author(s):  
Bojana Popovic ◽  
Ivana Bozic Antic ◽  
Tatjana Isailovic ◽  
Tamara Bogavac ◽  
Dusan Ilic ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Gonadal Dysfunction ◽  
Male Patients

scholarly journals Amphicrine carcinoma of the stomach and intestine: a clinicopathologic and pan-cancer transcriptome analysis of a distinct entity

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Dan Huang ◽  
Fei Ren ◽  
Shujuan Ni ◽  
Cong Tan ◽  
Weiwei Weng ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Expression Patterns ◽  
Biological Behavior ◽  
Low Grade ◽  
High Grade ◽  
Clinicopathologic Characteristics ◽  
Signet Ring ◽  
Cancer Transcriptome ◽  
Male Patients ◽  
Pan Cancer

Abstract Background and aim Amphicrine carcinoma, in which endocrine and epithelial cell constituents are present within the same cell, is very rare. This study characterized the clinicopathologic and survival analysis of this tumor, further compared the genetic diversities among amphicrine carcinoma and other tumors. Materials and methods The clinicopathologic characteristics and survival outcomes of amphicrine carcinoma in this study were analyzed. The pan-cancer transcriptome assay was utilized to compare the genetic expression profile of this entity with that of conventional adenocarcinoma or neuroendocrine tumors. Results Ten cases (all in male patients) were identified in the stomach or intestine, with a median patient age of 62 years. There were characteristic patterns in the tumors: tubular, fusion or single-file growth of goblet- or signet ring-like cells. Four tumors were classified as low-grade and 6 as high-grade according to the histologic architecture. All cases were positive for neuroendocrine markers (synaptophysin and chromogranin A) and showed intracellular mucin in the amphicrine components. Four cases exhibited mRNA expression patterns showing transcriptional homogeneity with conventional adenocarcinomas and genetic diversity from neuroendocrine tumors. During the follow-up period, 3 patients died of disease, all of whom had high-grade tumors. Patients with high-grade amphicrine carcinoma had worse outcomes than those with low-grade tumors. Conclusions This study confirms the morphological, immunostaining and transcriptome alterations in amphicrine carcinoma distinct from those in conventional adenocarcinomas and neuroendocrine tumors, but additional studies are warranted to determine the biological behavior and therapeutic response.

Gonadal dysfunction in adult male patients with thalassemia major: an update for clinicians caring for thalassemia

2017 ◽  
Vol 10 (12) ◽  
pp. 1095-1106 ◽  
Author(s):  
Vincenzo De Sanctis ◽  
Ashraf T. Soliman ◽  
Heba Elsedfy ◽  
Salvatore Di Maio ◽  
Duran Canatan ◽  
...  
Keyword(s):  
Adult Male ◽  
Thalassemia Major ◽  
Gonadal Dysfunction ◽  
Male Patients

scholarly journals Sexual dimorphism in small-intestinal neuroendocrine tumors: lower prevalence of mesenteric disease in premenopausal women

2022 ◽  
Author(s):  
Anela Blažević ◽  
Anand M Iyer ◽  
Marie-Louise F van Velthuysen ◽  
Johannes Hofland ◽  
Lindsey Oudijk ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Sexual Dimorphism ◽  
Tumor Cells ◽  
Neuroendocrine Tumors ◽  
Estrogen Receptor Alpha ◽  
Premenopausal Women ◽  
Primary Tumors ◽  
Tertiary Center ◽  
Male Patients ◽  
Small Intestinal

Abstract Context Small intestinal neuroendocrine tumors (SI-NETs) have a modest but significantly higher prevalence and worse prognosis in male patients. Objective This work aims to increase understanding of this sexual dimorphism in SI-NETs. Patients and Methods Retrospectively, SI-NET patients treated in a single tertiary center were included and analyzed for disease characteristics. Estrogen receptor 1 (ESR1) and 2 (ESR2), progesterone receptor (PGR) and androgen receptor (AR) mRNA expression was assessed in primary tumors and healthy intestine. Estrogen receptor alpha (ERα) and AR protein expression was analyzed by immunohistochemistry in primary tumors and mesenteric metastases. Results Of the 559 patients, 47% were female. Mesenteric metastasis/fibrosis was more prevalent in men (71/46%) than women (58/37%, P=0.001 and P = 0.027). In women, prevalence of mesenteric metastases increased gradually with age from 41.1% in women <50 years to 71.7% in women >70 years. Increased expression of ESR1 and AR mRNA was observed in primary tumors compared to healthy intestine (both P < 0.001). ERα staining was observed in tumor cells and stroma with a strong correlation between tumor cells of primary tumors and mesenteric metastases (rho=0.831, P=0.02), but not in stroma (rho=-0.037, P=0.91). AR expression was only found in stroma. Conclusion Sexual dimorphism in SI-NETs was most pronounced in mesenteric disease and the risk of mesenteric metastasis in women increased around menopause. The combination of increased ERα and AR expression in the SI-NET microenvironment suggests a modulating role of sex steroids in the development of the characteristic SI-NET mesenteric metastasis and associated fibrosis.

scholarly journals Association between Sex Hormone and Blood Uric Acid in Male Patients with Type 2 Diabetes

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Wen Cao ◽  
Ren-Dong Zheng ◽  
Shu-Hang Xu ◽  
Yao-Fu Fan ◽  
Hong-Ping Sun ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Uric Acid ◽  
Waist Circumference ◽  
Serum Uric Acid ◽  
Body Mass ◽  
Sex Hormone ◽  
Gonadal Dysfunction ◽  
Male Patients

The association between serum uric acid (SUA) level and sexual dysfunction in patients with diabetes is not well characterized. Type 2 diabetes mellitus (T2DM) causes metabolic disorders, including abnormal serum uric acid (SUA) levels. In this study, we enrolled 205 male patients with T2DM and investigated the relationship between sex hormone levels and SUA. Patients were divided into four groups based on SUA quartiles. On the other hand, based on the total testosterone (TT) level, patients were divided into three groups; SUA and other laboratory indices were determined. Increase in SUA level was significantly associated with decreased levels of TT, luteinizing hormone, follicle-stimulating hormone, sex hormone-binding globulin, and increased levels of dehydroepiandrosterone, age, body mass index (BMI), waist circumference, glycated hemoglobin, serum creatinine, and HOMA-IR levels. SUA, waist circumference, BMI, and HOMA-IR showed a negative correlation with TT level, while age showed a positive correlation with TT level. SUA and body mass index were found to be risk factors for gonadal dysfunction. Therefore, we conclude that hypogonadism of male patients with T2DM is related to SUA level.

Pituitary-Gonadal Dysfunction in Male Patients with Lung Cancer: Association with serum inhibin levels

1994 ◽  
Vol 33 (2) ◽  
pp. 177-180 ◽  
Author(s):  
Ulf Aasebø ◽  
Roy M. Bremnes ◽  
Frank H. De Jong ◽  
Asbjørn Aakvaag ◽  
Lars Slørdal
Keyword(s):  
Lung Cancer ◽  
Gonadal Dysfunction ◽  
Male Patients

Effects of Long-Term Erythropoietin Therapy on the Hypothalamo–Pituitary–Testicular Axis in Male Capd Patients

2001 ◽  
Vol 21 (5) ◽  
pp. 448-454 ◽  
Author(s):  
Bülent Tokgöz ◽  
Cengiz Utaş ◽  
Ayhan Dogukan ◽  
Muhammet Güven ◽  
Hülya Taşkapan ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Luteinizing Hormone ◽  
Healthy Volunteers ◽  
Free Testosterone ◽  
Blood Samples ◽  
Testosterone Levels ◽  
Gonadal Dysfunction ◽  
Before And After ◽  
Male Patients ◽  
Lh Rh

Objective Gonadal dysfunction has been recognized for a long time in uremic male patients. The present study assesses the hypothalamo–pituitary–testicular axis and growth hormone status in male continuous ambulatory peritoneal dialysis (CAPD) patients, before and after recombinant human erythropoietin (rHuEPO) therapy. Design Single-center prospective study. Subjects Ten anemic male patients with chronic renal insufficiency, and 11 healthy volunteers with normal renal function, matched for age, were included in the study. All patients were on CAPD therapy and none had received rHuEPO treatment previously. Main Outcome Measures Blood samples were collected between 0800 and 0900 hr from all patients for the determination of basal follicle stimulating hormone (FSH), luteinizing hormone (LH), and growth hormone (GH) levels. A luteinizing hormone-releasing hormone (LH-RH) stimulation test was carried out using LH-RH 100 mg intravenous as a bolus injection. Blood for FSH, LH, and GH determinations was drawn every 30 minutes during the 3-hour test period. Human chorionic gonadotropin (hCG) test was performed after 48 hours. After estimations of basal serum total and free testosterone levels, 2000 IU hCG was administered intramuscularly and repeated 48 hours later. Total and free testosterone levels were measured in blood samples collected before and 48 hours after two injections of hCG. After improvement in anemia with exogenous rHuEPO, LH-RH and hCG tests were repeated. Results Baseline FSH concentrations before and after rHuEPO treatment were slightly higher in CAPD patients than in healthy volunteers ( p = 0.85 and p = 0.70, respectively). Areas-under-the-curve (AUCs) for FSH secretion before and after rHuEPO treatment were also slightly higher in patients than in healthy volunteers ( p = 1.00 and p = 0.75, respectively). The pretreatment basal LH levels in patients were significantly higher than in controls ( p < 0.001). After the improvement in anemia with rHuEPO, serum LH levels declined significantly ( p < 0.05). The AUCs for LH secretion before and after rHuEPO treatment were significantly higher in patients than in controls ( p < 0.05). All patients had elevated basal levels of GH with paradoxical response to LH-RH. Baseline GH levels in patients were significantly higher than those in healthy subjects ( p < 0.001) before rHuEPO treatment. After treatment with rHuEPO, basal GH levels declined but did not normalize, and baseline levels of free testosterone increased significantly ( p < 0.05). Conclusion Anemic uremic male patients on CAPD have normal levels of testosterone with normal response to hCG administration, elevated basal levels of GH, and elevated basal levels of LH, with exaggerated response to LH-RH administration. Improvement in anemia with rHuEPO reduced the basal levels of LH and GH, but exaggerated the LH response; paradoxical GH response to LH-RH administration persisted. These results indicate a defect at the level of the hypothalamus and pituitary gland in uremic male patients undergoing CAPD, and that the improvement in anemia with rHuEPO partially restores some of these endocrine abnormalities.

scholarly journals Gonadal dysfunction in male patients with chronic renal failure undergoing hemodialysis

1985 ◽  
Vol 18 (5) ◽  
pp. 473-478
Author(s):  
Koichi Hasegawa ◽  
Motoo Oda ◽  
Hideyo Moriguchi ◽  
Teruo Okamoto ◽  
Kiichiro Kikunami ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Gonadal Dysfunction ◽  
Male Patients

Investigation of Gonadal Function, Puberty, and their relationship to Serum Ferritin in Male patients with β-Thalassemia major in Syria

2021 ◽  
pp. 3595-3602
Author(s):  
Roula Shakkour ◽  
Taghrid Hammoud ◽  
Yasser Mukhalalaty ◽  
Faizeh Al Quobaili
Keyword(s):  
Iron Overload ◽  
Serum Ferritin ◽  
Thalassemia Major ◽  
Delayed Puberty ◽  
Beta Thalassemia ◽  
Endocrine Disorders ◽  
Gonadal Function ◽  
Pubertal Status ◽  
Gonadal Dysfunction ◽  
Male Patients

Objectives: Endocrine disorders continue to affect the health of thalassemia patients, foremost of which is hypogonadism being the most frequent endocrine complication that involves 70-80% of beta-thalassemia major (β-TM) patients. Actually, the role of iron overload in endocrine complications is well known. Our study goals were to investigate gonadal function, assess pubertal status among Syrian male patients with β-TM and correlate hormonal panel with serum ferritin as the marker of iron overload. Methods: 56 β-TM regularly transfused male patients were enrolled in this study, they were 21.91±5.01 years old. FSH, LH, Total Testosterone, and Serum Ferritin were measured for all patients, 52 of them undergone pubertal status evaluation. Results: Results showed that 60.7% of patients suffered from hypogonadism, which was hypogonadotropic hypogonadism in 97.06% of them. Delayed puberty was seen in 7.7% of the patients, while arrested puberty was found in 82.69% of them. All patients had iron overload and 92.86% of them suffered from severe iron elevation. Both gonadal and pubertal status were independent of the serum ferritin levels (P=0.73), (P=0.81) respectively. There was significant positive correlation between FSH: LH (r=0.584, P=0.0001), FSH: Testosterone (r=0.562, P=0.0001), LH: Testosterone (r=0.746, P=0.0001), MCHC: Testosterone (r=0.292, P=0.038), and BMI: Hb (r=0.351, P=0.009). Conclusions: Our findings indicated that hypogonadism, arrested puberty and severe iron overload were highly prevalent among male patients with β-TM. Patients with better gonadal reserve have higher BMI than those with gonadal dysfunction. We suggest that hypogonadism in β-TM patients is not directly related to serum ferritin levels; other potential factors (such as chronic anemia, hypoxia, and genetic predisposition) may contribute. Also we suggest that adequate blood transfusion and appropriate iron chelation, along with regular evaluation for gonadal status and timely intervention can improve the management of aforementioned complications, thus ameliorating patients’ quality of life.

Geographic and demographic disparities in neuroendocrine tumors (NETs): A population-based study.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15694-e15694 ◽  
Author(s):  
Rohit Gosain ◽  
Somedeb Ball ◽  
Navpreet Kaur Rana ◽  
Adrienne Groman ◽  
Elizabeth Gage-Bouchard ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Tumor Biology ◽  
Sociodemographic Factors ◽  
Population Based ◽  
Population Based Study ◽  
Specific Mortality ◽  
Sociodemographic Disparities ◽  
Male Patients ◽  
Socio Demographic Factors

e15694 Background: The incidence and prevalence of Neuroendocrine Tumors (NETs) are rapidly rising. There are very few studies investigating the role of sociodemographic factors on NETs. The aim of our study was to identify the disparities in the NET population. Methods: We conducted a retrospective analysis utilizing the Surveillance, Epidemiology, and End Results (SEER) database, and studied NETs patient population from 1973 to 2015. Univariate and multivariate analyses were performed to evaluate patients’ disease-specific survival (DSS) and overall survival (OS). Different socio-demographic factors including location of residence: urban area (UA) versus rural area (RA), gender, race, insurance status and marital status were included in the analysis. Results: A total of 53,522[ RA: N = 9,053; UA: N = 43,981] patients were included in the analysis. The incidence of NETs was found to be rising in both RA and UA but more rapidly in UA. RA was associated with more advanced stage at presentation in comparison to UA (p < 0.001). Cause-specific mortality remained higher in RA than UA throughout the study period. In the multivariate model, RA had a trend towards poorer DSS (HR:1.03, p = 0.399) and a worse OS compared to UA (HR = 1.06, p = 0.0003). Blacks had a poorer OS compared to non-Hispanic Whites (HR = 1.16, p < 0.001). Multivariate analysis showed significantly worse DSS and OS in uninsured, single and male patients compared to insured, married and female patients respectively. Conclusions: Our study identified sociodemographic disparities on NET outcomes. Access to healthcare could be a potential contributing factor although differences in environmental exposure, health behavior and tumor biology could also be responsible. Further population-based studies are required to address these disparities.

Sign in / Sign up

Export Citation Format

Share Document